Henry Schein (NASDAQ:HSIC) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Thursday, September 13th.
Other equities research analysts have also issued reports about the stock. Robert W. Baird raised their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, August 7th. Stifel Nicolaus raised their price objective on shares of Henry Schein from $76.00 to $81.00 and gave the company a “hold” rating in a report on Tuesday, August 7th. BidaskClub raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Wednesday, August 22nd. Zacks Investment Research downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Saturday, July 14th. Finally, Craig Hallum increased their target price on shares of Henry Schein from $83.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $85.06.
Henry Schein stock traded up $1.19 during mid-day trading on Thursday, reaching $88.44. 2,898,188 shares of the company’s stock were exchanged, compared to its average volume of 1,574,212. The firm has a market cap of $13.02 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 2.45 and a beta of 0.97. Henry Schein has a twelve month low of $62.56 and a twelve month high of $90.52. The company has a quick ratio of 0.68, a current ratio of 1.29 and a debt-to-equity ratio of 0.34.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Monday, August 6th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.03. Henry Schein had a net margin of 3.15% and a return on equity of 20.40%. The company had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.31 billion. During the same period in the prior year, the business earned $0.88 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. On average, equities research analysts anticipate that Henry Schein will post 4.12 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Squar Milner Financial Services LLC acquired a new position in Henry Schein during the second quarter worth about $120,000. Piedmont Investment Advisors LLC acquired a new position in Henry Schein during the second quarter worth about $130,000. Fuller & Thaler Asset Management Inc. raised its position in Henry Schein by 57.1% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after acquiring an additional 800 shares during the last quarter. BerganKDV Wealth Management LLC acquired a new position in Henry Schein during the second quarter worth about $203,000. Finally, Quest Investment Management LLC acquired a new position in Henry Schein during the second quarter worth about $214,000. Hedge funds and other institutional investors own 96.65% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More: Stop Order Uses For Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.